Trial Profile
A Phase Ib Study Evaluating BGJ398 in Combination With Chemotherapeutic Regimen in Patients With Stage IV, Recurrent or Persistent Carcinoma of The Cervix and Other Solid Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Infigratinib (Primary) ; Paclitaxel (Primary)
- Indications Cervical cancer; Solid tumours
- Focus Adverse reactions
- 15 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 13 Dec 2014 New trial record